Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $37.1667.

Several brokerages have recently weighed in on TYRA. Wall Street Zen lowered shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, January 21st. Barclays began coverage on Tyra Biosciences in a research note on Tuesday, January 27th. They issued an “overweight” rating on the stock. William Blair initiated coverage on Tyra Biosciences in a report on Tuesday. They issued an “outperform” rating for the company. Finally, Jefferies Financial Group raised their target price on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd.

Insider Activity

In other news, Director Robert J. More sold 246,871 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the sale, the director owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. The trade was a 6.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corton Capital Inc. bought a new stake in shares of Tyra Biosciences during the second quarter worth $233,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Tyra Biosciences in the second quarter valued at about $326,000. AlphaQuest LLC lifted its position in Tyra Biosciences by 146.7% during the 2nd quarter. AlphaQuest LLC now owns 73,073 shares of the company’s stock worth $699,000 after buying an additional 43,451 shares in the last quarter. Sio Capital Management LLC grew its holdings in Tyra Biosciences by 94.5% during the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after acquiring an additional 393,657 shares during the last quarter. Finally, Walleye Capital LLC increased its position in Tyra Biosciences by 163.2% in the 2nd quarter. Walleye Capital LLC now owns 370,408 shares of the company’s stock valued at $3,545,000 after acquiring an additional 229,666 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $31.41 on Wednesday. Tyra Biosciences has a one year low of $6.42 and a one year high of $32.44. The stock has a fifty day moving average price of $27.22 and a 200 day moving average price of $18.59. The stock has a market cap of $1.68 billion, a P/E ratio of -16.80 and a beta of 1.07.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.